JP2023040169A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023040169A5 JP2023040169A5 JP2023001554A JP2023001554A JP2023040169A5 JP 2023040169 A5 JP2023040169 A5 JP 2023040169A5 JP 2023001554 A JP2023001554 A JP 2023001554A JP 2023001554 A JP2023001554 A JP 2023001554A JP 2023040169 A5 JP2023040169 A5 JP 2023040169A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- replaced
- asn
- lys
- arg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1706406.4A GB201706406D0 (en) | 2017-04-21 | 2017-04-21 | Method of treatment |
| GB1706404.9 | 2017-04-21 | ||
| GB1706406.4 | 2017-04-21 | ||
| GBGB1706404.9A GB201706404D0 (en) | 2017-04-21 | 2017-04-21 | Method of treatment |
| GBGB1706452.8A GB201706452D0 (en) | 2017-04-24 | 2017-04-24 | Method of treatment |
| GB1706452.8 | 2017-04-24 | ||
| JP2019556794A JP7209637B2 (ja) | 2017-04-21 | 2018-04-20 | 自己免疫性水疱症の治療のためのコバーシン |
| PCT/EP2018/060241 WO2018193122A1 (en) | 2017-04-21 | 2018-04-20 | Coversin for the treatment of autoimmune blistering diseases |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556794A Division JP7209637B2 (ja) | 2017-04-21 | 2018-04-20 | 自己免疫性水疱症の治療のためのコバーシン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023040169A JP2023040169A (ja) | 2023-03-22 |
| JP2023040169A5 true JP2023040169A5 (https=) | 2023-10-11 |
| JP7600278B2 JP7600278B2 (ja) | 2024-12-16 |
Family
ID=62235916
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556794A Active JP7209637B2 (ja) | 2017-04-21 | 2018-04-20 | 自己免疫性水疱症の治療のためのコバーシン |
| JP2023001554A Active JP7600278B2 (ja) | 2017-04-21 | 2023-01-10 | 自己免疫性水疱症の治療のためのコバーシン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556794A Active JP7209637B2 (ja) | 2017-04-21 | 2018-04-20 | 自己免疫性水疱症の治療のためのコバーシン |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11730792B2 (https=) |
| EP (2) | EP3612208B1 (https=) |
| JP (2) | JP7209637B2 (https=) |
| KR (1) | KR102656199B1 (https=) |
| CN (1) | CN110896606B (https=) |
| AU (1) | AU2018253962B2 (https=) |
| CA (1) | CA3059657A1 (https=) |
| DK (1) | DK3612208T5 (https=) |
| ES (1) | ES2945433T3 (https=) |
| IL (1) | IL269895B2 (https=) |
| PL (1) | PL3612208T3 (https=) |
| WO (1) | WO2018193122A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201410116D0 (en) | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| ES2945433T3 (es) | 2017-04-21 | 2023-07-03 | Volution Immuno Pharmaceuticals Sa | Coversina para el tratamiento de enfermedades ampollares autoinmunes |
| CN110831617A (zh) * | 2017-04-21 | 2020-02-21 | 沃卢申伊缪诺制药公司 | 用于治疗瘢痕性眼部发炎性病症的Coversin |
| GB201706406D0 (en) | 2017-04-21 | 2017-06-07 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| US20220047673A1 (en) * | 2018-09-10 | 2022-02-17 | Volution Immuno Pharmaceuticals Sa | Coversin for Use in the Treatment of Rheumatic Diseases |
| GB201905810D0 (en) * | 2019-04-25 | 2019-06-05 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| JP2023503776A (ja) * | 2019-09-27 | 2023-02-01 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | 造血幹細胞移植後の血栓性微小血管症（ｈｓｃｔ－ｔｍａ）の治療方法 |
| GB202218084D0 (en) * | 2022-12-01 | 2023-01-18 | Volution Immuno Pharmaceuticals Sa | Fusion proteins |
| GB202408081D0 (en) | 2024-06-06 | 2024-07-24 | Volution Immuno Pharmaceuticals Sa | Methods of removing impurities |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| JP4772667B2 (ja) | 2003-06-02 | 2011-09-14 | エヴォルーテック・リミテッド | 補体阻害剤 |
| EP1739078A1 (de) * | 2005-05-30 | 2007-01-03 | Jerini AG | C5a-Rezeptor-Antagonisten |
| GB0518443D0 (en) | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
| WO2007095230A2 (en) | 2006-02-13 | 2007-08-23 | The Trustees Of The University Of Pennsylvania | TREATMENT OF AUTOIMMUNE BLISTERING DISEASE USING ANTI-IgE ANTIBODY |
| GB0617734D0 (en) | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| PL2061501T3 (pl) | 2006-09-08 | 2016-01-29 | Volution Immuno Pharmaceuticals Sa | Sposób leczenia zaburzeń oddechowych |
| JP2010521194A (ja) | 2007-03-22 | 2010-06-24 | ノバルティス アーゲー | Ｃ５抗原およびその使用 |
| ATE502114T1 (de) | 2007-06-21 | 2011-04-15 | Univ Muenchen Tech | Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität |
| GB0802116D0 (en) * | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
| WO2011056972A2 (en) * | 2009-11-04 | 2011-05-12 | Case Western Reserve University | Compositions and methods of treating a t cell mediated disorder |
| JP2012505160A (ja) * | 2008-10-06 | 2012-03-01 | カロラス セラピューティクス， インク． | 炎症を処置する方法 |
| GB0906779D0 (en) * | 2009-04-20 | 2009-06-03 | Natural Environment Res Council | Composition |
| NZ597259A (en) * | 2009-06-23 | 2014-04-30 | Alexion Pharma Inc | Bispecific antibodies that bind to complement proteins |
| AU2011204483B2 (en) | 2010-01-08 | 2016-02-11 | Volution Immuno Pharmaceuticals Sa | EV576 for use in the treatment of viral infections of the respiratory tract |
| CN103796667A (zh) | 2011-06-22 | 2014-05-14 | 艾普莱斯制药公司 | 用补体抑制剂治疗慢性障碍的方法 |
| TW201418707A (zh) | 2012-09-21 | 2014-05-16 | Alexion Pharma Inc | 補體組分ｃ５拮抗劑之篩選分析 |
| ES2768648T3 (es) | 2013-03-29 | 2020-06-23 | Alexion Pharma Inc | Composiciones y métodos para aumentar la semivida en suero de un agente terapéutico dirigido a C5 del complemento |
| GB201410031D0 (en) | 2014-06-05 | 2014-07-16 | Isis Innovation | Polypeptides and uses thereof |
| GB201410116D0 (en) | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| US20160168237A1 (en) * | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | Method for treating a complement mediated disorder caused by an infectious agent in a patient |
| EP3250230B9 (en) | 2015-01-28 | 2022-02-23 | RA Pharmaceuticals, Inc. | Modulators of complement activity |
| CA2988313A1 (en) | 2015-06-08 | 2016-12-15 | Volution Immuno Pharmaceuticals Sa | Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease |
| WO2016200627A1 (en) | 2015-06-09 | 2016-12-15 | Children's Hospital Medical Center | Dosing algorithm for complement inhibitor |
| EP4365291A3 (en) | 2015-06-12 | 2024-08-14 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| WO2017044811A1 (en) | 2015-09-11 | 2017-03-16 | Bruce Andrien | Recombinant glycosylated eculizumab and eculizumab variants |
| ES2945433T3 (es) | 2017-04-21 | 2023-07-03 | Volution Immuno Pharmaceuticals Sa | Coversina para el tratamiento de enfermedades ampollares autoinmunes |
| GB201706406D0 (en) * | 2017-04-21 | 2017-06-07 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| CN110831617A (zh) | 2017-04-21 | 2020-02-21 | 沃卢申伊缪诺制药公司 | 用于治疗瘢痕性眼部发炎性病症的Coversin |
-
2018
- 2018-04-20 ES ES18726731T patent/ES2945433T3/es active Active
- 2018-04-20 CA CA3059657A patent/CA3059657A1/en active Pending
- 2018-04-20 US US16/603,352 patent/US11730792B2/en active Active
- 2018-04-20 EP EP18726731.5A patent/EP3612208B1/en active Active
- 2018-04-20 DK DK18726731.5T patent/DK3612208T5/da active
- 2018-04-20 WO PCT/EP2018/060241 patent/WO2018193122A1/en not_active Ceased
- 2018-04-20 CN CN201880041710.5A patent/CN110896606B/zh active Active
- 2018-04-20 AU AU2018253962A patent/AU2018253962B2/en active Active
- 2018-04-20 JP JP2019556794A patent/JP7209637B2/ja active Active
- 2018-04-20 EP EP23166056.4A patent/EP4275696A1/en active Pending
- 2018-04-20 IL IL269895A patent/IL269895B2/en unknown
- 2018-04-20 PL PL18726731.5T patent/PL3612208T3/pl unknown
- 2018-04-20 KR KR1020197031711A patent/KR102656199B1/ko active Active
-
2023
- 2023-01-10 JP JP2023001554A patent/JP7600278B2/ja active Active
- 2023-06-09 US US18/332,191 patent/US20240009270A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023040169A5 (https=) | ||
| JP2021510162A5 (https=) | ||
| JP2021534220A5 (https=) | ||
| Kaspar et al. | Future directions for peptide therapeutics development | |
| TWI436776B (zh) | Ｆｇｆ２１突變體及其用途 | |
| JP2024150674A5 (https=) | ||
| JP6809789B2 (ja) | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 | |
| JP2021533779A5 (https=) | ||
| JP4398644B2 (ja) | ＥｒｂＢ界面ペプチド擬態およびその使用方法 | |
| JP2017538395A5 (https=) | ||
| AU2020242144B2 (en) | Combined pharmaceutical composition for treating small cell lung cancer | |
| JPWO2019140050A5 (https=) | ||
| CN1281468A (zh) | 用抗ErbB2抗体治疗 | |
| US20230192887A1 (en) | Engineered anti-her2 bispecific proteins | |
| JP2021521781A5 (https=) | ||
| JP2020517627A5 (https=) | ||
| JP2021514354A5 (https=) | ||
| JPWO2020059847A5 (https=) | ||
| JP2023503472A (ja) | 長時間作用型ｇｄｆ１５融合タンパク質およびそれを含む医薬組成物 | |
| JPWO2021116182A5 (https=) | ||
| JPWO2020041604A5 (https=) | ||
| JP2021522231A (ja) | チオエーテル環状ペプチドアミリン受容体調節因子 | |
| TW202541838A (zh) | 抗ｃｄ３８抗體在治療新診斷的多發性骨髓瘤中之用途 | |
| JPWO2022129560A5 (https=) | ||
| JPWO2021052349A5 (https=) |